Immune - cell death index in hepatocellular carcinoma: a multi-omics and machine learning study for prognosis and immunotherapy prediction - Takeaways - MDSpire

Immune - cell death index in hepatocellular carcinoma: a multi-omics and machine learning study for prognosis and immunotherapy prediction

  • By

  • Yi Zhang

  • Haiyu Zhao

  • Yunpeng Zhai

  • Chongyang Wang

  • Zhenya Wang

  • Ruopeng Liang

  • June 11, 2026

  • 0 min

Share

  • 1

    Hepatocellular carcinoma (HCC) is a highly heterogeneous cancer with significant individual disparities in immunotherapy response.

  • 2

    The study developed the hepatocellular carcinoma consensus immune-cell death index (HICDI) using multi-omics data and machine learning.

  • 3

    Patients with a low HICDI score showed improved overall survival and better responses to immunotherapy compared to those with a high score.

  • 4

    The high HICDI group was associated with 'cold' tumors, characterized by immune suppression, suggesting alternative therapies like paclitaxel.

  • 5

    Kinesin family member 2C was identified as a potential oncogene and therapeutic target, highlighting its role in HCC progression.

Original Source(s)

Immune - cell death index in hepatocellular carcinoma: a multi-omics and machine learning study for prognosis and immunotherapy prediction

  • by Yi Zhang, Haiyu Zhao, Yunpeng Zhai, Chongyang Wang, Zhenya Wang, Ruopeng Liang

  • June 11, 2026

Related Content

Viable CAR T-cells remain detectable in cerebrospinal fluid in patients with grade ≥3 ICANS despite corticosteroid therapy

Coexistence of rectal adenocarcinoma and rectal and lymph node tuberculosis: a case report with a limited narrative review

Disease site as an independent predictor of survival in radioiodine-refractory thyroid cancer